Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Business Wire•28/10/2026•07:00 ET
0
Key Highlights
- ➤Novocure and Verastem collaborate on pancreatic cancer trial combining TTFields and VS-7375
- ➤Novocure will manage and fund clinical trial operations; Verastem will supply VS-7375
- ➤Trial plans to evaluate safety and tolerability in approximately 25 patients
- ➤Patient enrollment is expected to begin in 2027
Expert Statements
Uri Weinberg, Chief Medical and Innovation Officer, Novocure
“Based on results we observed in pre-clinical models, we believe that the physical modality of Tumor Treating Fields therapy used together with a KRAS inhibitor has the potential to be an effective new treatment approach in pancreatic cancer.”
Michael Kauffman, President of Development, Verastem Oncology
“This collaboration will allow us to explore whether these treatment approaches, when used together, can drive deeper and more durable responses for these patients living with pancreatic cancer.”
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer.
Get started
Create a free account to read the full story.